Palvella Therapeutics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Palvella Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 4 currently recruiting 5 completed top decile by trial count

Palvella Therapeutics: 9 sponsored US clinical trials, 4 recruiting.

Palvella Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pachyonychia Congenita, with 3 trials.

Top-decile sponsor footprint

Palvella Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077
RECRUITING Phase 2

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
RECRUITING Phase 3

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480
RECRUITING Phase 3

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

NCT05643872
COMPLETED Phase 2

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

NCT05050149
COMPLETED Phase 3

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
COMPLETED Phase 2

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486
COMPLETED Phase 3

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

NCT04520750
COMPLETED Phase 2

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

NCT03920228

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 4

Therapeutic Areas

Pachyonychia Congenita 3
Cutaneous Venous Malformations 1
Microcystic Lymphatic Malformation 1

What is open in the Palvella Therapeutics pipeline

4 recruiting of 9 indexed (44% open); 5 completed (56%).

Phase mix: 4 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Pachyonychia Congenita (3 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Palvella Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 44% open enrollment, not the therapeutic-area sidebar.

Palvella Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 51015202530 0%10%20%30%40%50% Total trials Recruiting share Palvella Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAmerican Heart AssociationAscendis Pharma A/SCullinan TherapeuticsMarquette University
Palvella Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Palvella Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 44% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Palvella Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Palvella Therapeutics or any single study.

  • 4 of Palvella Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pachyonychia Congenita is the condition Palvella Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pachyonychia Congenita trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Palvella Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.